The interplay between human STING genotype and bacterial NADase activity.
What’s behind the recent surge in Apellis’ stock price? Growing confidence in the safety of its eye treatment
Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s
August 14, 2023